Supported by GSK, "Happy Breath", COPD Tiered Diagnosis and Treatment Project (“the project”) was launched in Beijing today.
These press releases are intended for business journalists and analysts/investors
Total EPS 24.8p, +49% AER, +46% CER; Adjusted EPS 32.5p, +3% AER, flat CER.
Flixotide Nebules (generic name: Fluticasone Propionate Nebuliser Suspension) has been approved by the China Food and Drug Administration (CFDA), for the treatment of mild to moderate asthma acute exacerbations in children and adolescents aged 4 – 16 years.
ViiV Healthcare1, a joint venture in which GSK is the majority shareholder, released the interim results from the DAWNING study2 at the recent International AIDS Conference
GSK China partners with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience
Today, GSK China and Ali Health jointly announced a strategic partnership to launch an innovative adult vaccination service system.
GSK today announced that Triumeq (generic name: dolutegravir, abacavir and lamivudine all-in-one tablet), the innovative antiretroviral (ARV) drug by its subsidiary joint venture ViiV Healthcare1, was granted approval by the China Food and Drug Administration (CFDA).
Today, on the occasion of World Hepatitis Day, under the guidance and support of the National Health and Family Planning Commission (NHFPC), GSK and the China Health Promotion Foundation (CHPF) signed a Letter of Intent.
The Ministry of Human Resources and Social Security (MOHRSS) today announced the results of the national health insurance negotiations, and two GSK products, Tykerb (Lapatinib) and Seroxat CR (Paroxetine), are included in the national reimbursement drug list (NRDL).